Welcome to CSNpharm! For Research Use Only!

c-RET

c-RET

Cat. No. Product Name CAS No. Information
CSN12405 Fedratinib   936091-26-8 TG 101348 is an inhibitor of JAK2 with an IC of 6 nM and also inhibits related kinases FLT3, RET, and JAK3 with less potent activity, having IC values of 25, 17 and 169 nM, respectively.
CSN26200 SPP-86 1357349-91-7 SPP-86 is a potent and selective cell permeable inhibitor of RET tyrosine kinase( IC50 :8 nM). SPP-86 inhibits RET-induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling, also inhibits RET-induced estrogen receptorα (ERα) phosphorylation in MCF7 cells.
CSN25546 Selpercatinib 2152628-33-4 Selpercatinib is a potent and specific RET inhibitor with IC50 values of 1 nM, 2 nM, 2 nM, 4 nM, 2 nM, 2 nM for WT RET, RET V804M, RET V804L, RET A883F, RET M918T and RET S891A respectively.
CSN26135 RET V804M-IN-1 2414909-94-5 RETV804M kinase inhibitor is a selective c-RET (V804M) inhibitor with IC50 value of 20nM.
CSN13099 Regorafenib 755037-03-7 Regorafenib is a multi-target inhibitor for VEGFR123, PDGFR, Kit, RET and Raf-1 with IC50 of 134.246 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
CSN25230 ODM-203 1430723-35-5 ODM-203 is a selective inhibitor of FGFR and VEGFR with IC50 values of 11, 16, 6, 35nM for recombinant FGFR1-4 and 26, 9, 5nM for VEGFR1-3, respectively.
CSN23893 RET-IN-1 2222755-14-6 LOXO-292 is a selective and potent RET inhibitor and an investigational drug in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase.
CSN26936 JNJ-38158471 951151-97-6 JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor, with an IC50 of 40 nM. JNJ-38158471 also inhibits Ret and Kit with IC50s of 180 and 500 nM, respectively .
CSN24470 GSK3179106   1627856-64-7 GSK3179106 is a potent, selective and gut-restricted RET kinase inhibitor with IC50 value of 0.4nM.
CSN27527 Fedratinib hydrochloride hydrate 1374744-69-0 Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research.
CSN27593 DUN73423 2414373-42-3 DUN73423 is a RET/KDR-Selective inhibitor of RETV804M Kinase with IC50 of 7 nM.
CSN12423 Danusertib 827318-97-8 Danusertib is a pyrrolo-pyrazole and small molecule Aurora kinases inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively. It is modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc.
CSN15883 Agerafenib 1188910-76-0 CEP-32496 is an inhibitor of BRAF V600E (IC50 14 nM), WT (IC50 34 nM) and c-Raf (IC50 39 nM). It also exhibits certain inhibitory activity against Abl-1, c-Kit, Ret, PDGFR and VEGFR2.
CSN28779 BT-13 924537-98-4 BT13 acts as direct RetA agonists and interacts with GFRα1 at the allosteric site in GDNF-GFRα1-RetA complex. It was similar to NGF and ARTN in selectively promoting neurite outgrowth from the peptidergic class of adult sensory neurons in culture, but was opposite to ARTN in causing neurite elongation without affecting initiation.
CSN22922 Pralsetinib 2097132-94-8 Blu667 is a highly potent and selective RET inhibitor with IC50 value of 0.4nM.
CSN19120 BBT594 882405-89-2 BBT594 is a potentreceptor tyrosine kinase RET inhibitor, used for cancer treatment.
CSN18365 AST 487 630124-46-8 AST-487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM. AST487 also inhibits RET,KDR,c-KIT,and c-ABL kinase with IC50 values below 1 μM.
CSN22316 AD80   1384071-99-1 AD80 is a multikinase inhibitor with inhibitions onRETRAF SRC andS6K
<< PREV 1 NEXT >>